Targeting vulnerability in B-cell development leads to novel drug combination for leukemia
By characterizing B-cells’ developmental stages, scientists at St. Jude Children’s Research Hospital designed and tested a drug...
May 3, 2024
Besponsa ‘More Effective’ at Driving Remission for Pediatric B-ALL
Besponsa provides another — and potentially more effective — option outside of traditional chemotherapy for pediatric patients with...
Apr 24, 2024
New study achieves 99 percent remission in children who relapse with most common childhood cancer
A recent collaboration with colleagues in Shanghai Children’s Medical Center has found a new immunotherapy combination that resulted in ...
Dec 20, 2022
Study identifies chromosomal abnormalities associated with relapse in frequent subtype of childhood
An international research team coordinated by Dr. Oscar Molina and Dr. Pablo Menéndez, from the Josep Carreras Leukaemia Research ...
Jul 11, 2022
Exploiting a vulnerability in an aggressive leukemia affecting babies
New work finds that the cells that cause relapse in MLL-rearranged B-ALL can morph between two states, and that targeting one of these...
Jun 2, 2022
Research lays a foundation for prevention of the most common childhood cancer
Scientists at St. Jude Children’s Research Hospital and the Cancer Research Center in Spain blocked development of acute lymphoblastic...
Feb 8, 2022
Immunotherapy drug improves outcomes for some children with relapsed leukemia
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for...
Dec 11, 2019